3-(3-甲酰基-4-羟基苄基)吡啶 | 85666-04-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 3-(3-甲酰基-4-羟基苄基)吡啶
• 英文名称: 3-(3-formyl-4-hydroxybenzyl)pyridine
• 英文别名: 3-(3'-formyl-4'-hydroxybenzyl)pyridine；2-hydroxy-5-(pyridin-3-ylmethyl)benzaldehyde
• CAS: 85666-04-2
• 化学式: C₁₃H₁₁NO₂
• 分子量: 213.236
• InChiKey: IKTPTXRNENTYQS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(3-甲酰基-4-羟基苄基)吡啶 在 二环己烷并-18-冠醚-6 、 sodium hydride 、 间氯过氧苯甲酸 、 三氯氧磷 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 50.5h， 生成 5-<3-(5-chloropyridyl)methyl>-2-benzofurancarboxylic acid ethyl ester
  参考文献：
  名称：

  Thromboxane A2 synthase inhibitors. 5-(3-Pyridylmethyl)benzofuran-2-carboxylic acids

  摘要：

  The synthesis and screening of a series of 5-(3-pyridylmethyl)benzofuran-2-carboxylic acids as selective thromboxane A2 (TxA2) synthase inhibitors is outlined. The ability of these compounds to inhibit TxA2 biosynthesis was assayed using microsomal enzyme from human platelets. Substitution of the benzofuran ring caused small changes in potency; modification of the carboxylic acid group caused modest reductions in potency, and substitution of the pyridine ring resulted in large reductions of potency. 5-(3-Pyridylmethyl)benzofuran-2-carboxylic acid sodium salt (9b, sodium furegrelate) was chosen for further evaluation as a TxA2 synthase inhibitor.

  DOI：

  10.1021/jm00158a024
• 作为产物：
  描述：

  3-(4'-nitrobenzyl)pyridine 在 palladium on activated charcoal 硫酸 、 水 、 氢气 、 三氟乙酸 、 sodium nitrite 作用下， 以 甲醇 为溶剂， 反应 6.5h， 生成 3-(3-甲酰基-4-羟基苄基)吡啶
  参考文献：
  名称：

  Thromboxane A2 synthase inhibitors. 5-(3-Pyridylmethyl)benzofuran-2-carboxylic acids

  摘要：

  The synthesis and screening of a series of 5-(3-pyridylmethyl)benzofuran-2-carboxylic acids as selective thromboxane A2 (TxA2) synthase inhibitors is outlined. The ability of these compounds to inhibit TxA2 biosynthesis was assayed using microsomal enzyme from human platelets. Substitution of the benzofuran ring caused small changes in potency; modification of the carboxylic acid group caused modest reductions in potency, and substitution of the pyridine ring resulted in large reductions of potency. 5-(3-Pyridylmethyl)benzofuran-2-carboxylic acid sodium salt (9b, sodium furegrelate) was chosen for further evaluation as a TxA2 synthase inhibitor.

  DOI：

  10.1021/jm00158a024

文献信息

• N-hydroxyurea derivative and pharmaceutical composition containing the same
  申请人：Nikken Chemicals Co., LTD

  公开号：US06291482B1

  公开（公告）日：2001-09-18

  A novel N-hydroxyurea derivative represented by formula (I) and having antiallergic and anti-inflammatory effects, i.e., N-hydroxy-N-[6-(3-pyridylmethyl)-2H-1-benzopyran-3-ylmethyl]urea: and medicines containing the above urea derivative or a pharmacologically acceptable salt thereof, or a hydrate or solvate thereof as the active ingredient, particularly antiallergic or anti-inflammatory agent, especially antiasthmatic.

  一种新的N-羟基脲衍生物，表示为式(I)，具有抗过敏和抗炎作用，即N-羟基-N-[6-(3-吡啶甲基)-2H-1-苯并吡喃-3-基甲基]脲： 以及含有上述脲衍生物或其药理学上可接受的盐、水合物或溶剂化合物作为活性成分的药物，特别是抗过敏或抗炎药物，尤其是抗哮喘药。
• Pyridyl-substituted-benzofurans
  申请人：The Upjohn Company

  公开号：US04495357A1

  公开（公告）日：1985-01-22

  The present invention provides novel pyridinyl-benzofurans and derivatives thereof which are useful as thromboxane A.sub.2 (TXA.sub.2) synthetase inhibitors and as such represent potent pharmacological agents.

  本发明提供了一种新型吡啶基苯并呋喃及其衍生物，可作为血栓素A.sub.2（TXA.sub.2）合成酶抑制剂，因此代表了强效的药理剂。
• Pyridinyl and imidazolyl derivatives of benzofurans and benzothiophenes
  申请人：THE UPJOHN COMPANY

  公开号：EP0069521A2

  公开（公告）日：1983-01-12

  Compounds of the formula wherein Z, is pyridinyl or imidazolyl; X, is -(CH2)n-, -0-, -S-, -SO-, -SO2. -CH2-O-, -0-CH2-, -CH2-NR3-, -NR3-CH2-. -CHOH- or -CO-; Y, is -O- or -S-; R2 is H. C1-3 alkyl, phenyl or optionally esterified carboxyl; R7 is H, CH2OH, optionally esterified carboxyl, CN, aminomethyl. aminocarbonyl, CHO or a ketone; either Rg and R12 are independently selected from hydrogen, hydroxy, C1-4 alkyl, fluorine, chlorine, bromine and methoxy, or R9 and R12 are attached to adjacent carbon atoms and together are -O-CH2-O-; = represents a single bond (in which case the compound may be in enantiomeric or racemic form) or a double bond; and m and n are 0,1, 2,3 or 4. These compounds can inhibit TXA2 synthetase.

  式中的化合物 其中 Z 是吡啶基或咪唑基； X 是-(CH2)n-、-0-、-S-、-SO-、-SO2.-CH2-O，-0-CH2-，-CH2-NR3-，-NR3-CH2-。-CHOH-或-CO-；Y 是-O-或-S-；R2 是 H、C1-3 烷基、苯基或任选酯化的羧基；R7 是 H、CH2OH、任选酯化的羧基、CN、氨甲基或者 Rg 和 R12 独立选自氢、羟基、C1-4 烷基、氟、氯、溴和甲氧基，或者 R9 和 R12 连接到相邻的碳原子上，并共同为 -O-CH2-O-； = 代表单键（在这种情况下，化合物可能是对映异构体或外消旋体）或双键；m 和 n 分别为 0、1、2、3 或 4。这些化合物可抑制 TXA2 合成酶。
• N-HYDROXYUREA DERIVATIVE AND MEDICINE CONTAINING THE SAME
  申请人：Nikken Chemicals Company, Limited

  公开号：EP1044974A1

  公开（公告）日：2000-10-18

  A novel N-hydroxyurea derivative represented by formula (I) and having antiallergic and anti-inflammatory effects, i.e., N-hydroxy-N-[6-(3-pyridylmethyl)-2H-1-benzopyran-3-ylmethyl]urea: and medicines containing the above urea derivative or a pharmacologically acceptable salt thereof, or a hydrate or solvate thereof as the active ingredient, particularly antiallergic or anti-inflammatory agent, especially antiasthmatic.

  一种由式(I)代表并具有抗过敏和抗炎作用的新型 N-羟基脲衍生物，即 N-羟基-N-[6-(3-吡啶基甲基)-2H-1-苯并吡喃-3-基甲基]脲： 以及含有上述脲衍生物或其药理学上可接受的盐、或其水合物或溶液作为活性成分的药物，特别是抗过敏或消炎药，尤其是抗哮喘药。
• J. Med. Chem. 1986, 29, 1461-1468
  作者：

  DOI：——

  日期：——